Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

OSIMERTINIB vs OXALIPLATIN: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

OSIMERTINIB vs OXALIPLATIN: Safety Overview

Metric OSIMERTINIB OXALIPLATIN
Total FAERS Reports 27,750 56,406
Deaths Reported 12,456 6,501
Death Rate 44.9% 11.5%
Hospitalizations 5,277 21,980
Average Patient Age 68.2 yrs 61.5 yrs
% Female Patients 66.0% 42.1%
FDA Approval Date Nov 13, 2015 Apr 28, 2011
Manufacturer AstraZeneca Pharmaceuticals LP Camber Pharmaceuticals, Inc.
Route ORAL INTRAVENOUS
Marketing Status Prescription Discontinued